| Trial ID: | L2475 |
| Source ID: | NCT00303394
|
| Associated Drug: |
Il-1ra
|
| Title: |
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: IL-1Ra
|
| Outcome Measures: |
Primary: HbA1c | Secondary: Insulin requirement|Stimulated C peptide and insulin|Fasting plasma glucose (FPG)|Serum cytokine levels, CRP|Insulin secretion and Insulin-sensitivity index derived from an OGTT with insulin and glucose measurements.|In a subgroup of patients, insulin-sensitivity assessed by clamp techniques|Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.
|
| Sponsor/Collaborators: |
Sponsor: University of Zurich | Collaborators: Steno Diabetes Center Copenhagen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
72
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-04
|
| Completion Date: |
2006-03
|
| Results First Posted: |
|
| Last Update Posted: |
2007-03-05
|
| Locations: |
Steno Diabetes Center, Gentofte, Copenhagen, 2280, Denmark|University Hospital of Zurich, Division of Endocrinology and Diabetes, Zurich, 8091, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT00303394
|
